HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Update

HCW Biologics Inc. (NASDAQ:HCWB) was the target of a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 57,608 shares, a growth of 142.5% from the February 12th total of 23,758 shares. Approximately 3.1% of the company’s shares are short sold. Based on an average trading volume of 163,691 shares, the days-to-cover ratio is presently 0.4 days. Based on an average trading volume of 163,691 shares, the days-to-cover ratio is presently 0.4 days. Approximately 3.1% of the company’s shares are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC acquired a new stake in HCW Biologics Inc. (NASDAQ:HCWB) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 2.96% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $35.00.

HCW Biologics Stock Down 7.7%

NASDAQ:HCWB traded down $0.04 during trading hours on Friday, reaching $0.52. The company had a trading volume of 38,917 shares, compared to its average volume of 164,785. HCW Biologics has a twelve month low of $0.47 and a twelve month high of $17.80. The firm has a market cap of $1.69 million, a price-to-earnings ratio of -0.04 and a beta of 0.79. The business’s 50-day simple moving average is $0.93 and its two-hundred day simple moving average is $2.44.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.